Dosage is weight-based: 80 mg once daily for patients <100 kg, 100 mg once daily for ≥100 kg, adjusted for CYP2C8 inhibitors.

Weight-Adjusted Dosing and Drug Interaction Management

REZDIFFRA is administered orally once daily, with or without food. For patients on moderate CYP2C8 inhibitors (e.g., clopidogrel), reduce dosage to 60 mg (<100 kg) or 80 mg (≥100 kg). Avoid concomitant use with strong CYP2C8 inhibitors (e.g., gemfibrozil) or OATP1B1/1B3 inhibitors (e.g., cyclosporine). Tablets are available in 60 mg, 80 mg, and 100 mg strengths. Dosage adjustments are not required for mild renal impairment; severe renal impairment data are lacking.